From Poison to Precision: One Patient with Lung Adenocarcinoma Across Oncology Eras

Abstract

Advanced lung adenocarcinoma has historically been associated with poor survival and substantial treatment-related morbidity, reflecting limited diagnostic precision and non-selective therapeutic strategies. This case-based review traces the evolution of management through three eras using a representative presentation of a 60-year-old woman with advanced disease. In the 1970s–1980s, diagnosis relied on chest radiography, sputum cytology, and invasive biopsy, with inaccurate staging due to limited imaging and no molecular characterization. Treatment was largely palliative, centered on radiotherapy, surgery in select cases, and first- and second-generation platinum-based chemotherapy, which offered modest survival benefits at the cost of significant toxicity. Contemporary management in the 2020s is defined by next-generation sequencing and molecular stratification, enabling the identification of actionable oncogenic drivers and immune biomarkers. Tyrosine kinase inhibitors targeting EGFR, ALK, and other alterations, alongside immune checkpoint inhibitors directed at the PD-1/PD-L1 axis, have transformed outcomes, delivering improved survival, reduced severe adverse events, and durable disease control in selected patients. Looking ahead, emerging innovations promise further individualization of care. Personalized neoantigen vaccines derived from tumour-specific sequencing aim to elicit highly targeted immune responses with minimal off-target toxicity, particularly when combined with immune checkpoint blockade. Collectively, these advances illustrate a paradigm shift from broadly cytotoxic therapy toward precision oncology, highlighting both the rapid progress achieved in lung adenocarcinoma management and the substantial opportunity to further improve patient outcomes in the decades ahead.